Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis

CONCLUSIONS: There is lack of evidence for the efficacy and safety of anti-IgE (omalizumab) therapy in people with cystic fibrosis and allergic bronchopulmonary aspergillosis. There is a need for large prospective randomized controlled studies of anti-IgE therapy in people with cystic fibrosis and allergic bronchopulmonary aspergillosis with both clinical and laboratory outcome measures such as steroid requirement, allergic bronchopulmonary aspergillosis exacerbations and lung function.PMID:34550603 | DOI:10.1002/14651858.CD010288.pub5

Source: Cochrane Database of Systematic Reviews - September 22, 2021 Category: General Medicine Authors: Kana R Jat Dinesh K Walia Anju Khairwa Source Type: research